Skip to content
OpenTrain AIFor AI Companies

HFEPX · Eval paper review

Can Language Models Identify Side Effects of Breast Cancer Radiation Treatments?

Natalie Seah, Danielle S. Bitterman, Daphna Spiegel, Thomas Hartvigsen

Published

May 8, 2026

Citations

0

Trust level

Moderate

Usefulness score

65/100 (Medium)

Extraction confidence

70% (Moderate)

Derived from extracted protocol signals and abstract evidence.

Rater population

Domain Experts

Signals refreshed

May 18, 2026

Should you rely on this paper?

This paper has useful evaluation signal, but protocol completeness is partial; pair it with related papers before deciding implementation strategy.

Use this for comparison and orientation, not as your only source.

Best use

Secondary protocol comparison source

Use if you need

A secondary eval reference to pair with stronger protocol papers.

What to verify

Validate the evaluation procedure and quality controls in the full paper before operational use.

Main weakness

No major weakness surfaced.

Human feedback signal
Detected
From extracted signals
Evaluation signal
Detected
Eval setup described
Usefulness for eval research
65/100
Moderate-confidence candidate

Useful as a secondary reference; validate protocol details against neighboring papers.

Abstract

Accurately communicating the side effects of cancer treatments to cancer survivors is critical, particularly in settings such as informed consent, where clinicians must clearly and comprehensively convey potential treatment toxicities. However, this task remains challenging due to clinical knowledge deficits about adverse treatment effects and fragmentation across electronic health record (EHR) systems. Large language models (LLMs) have the potential to assist in this task, though their reliability in oncology survivorship contexts remains poorly understood. We present a deployment-oriented stress-testing framework for evaluating LLM-generated radiation side effect lists in breast cancer treatment and survivorship care. Using 21 breast cancer patient profiles, we construct paired patient clinical scenarios that differ only in radiotherapy regimens to evaluate seven instruction-tuned LLMs under multiple prompting regimes. We then compare LLM outputs to a clinician-curated reference derived from informed consent documents at two major academic medical centers and developed by a team including more than seven breast radiation oncologists. The reference maps radiation dose-fractionation, fields, and locations to associated toxicities, broken down by frequency and temporal onset. Across models, we reveal sensitivity to minor documentation changes, trade-offs between precision and recall, and systematic under-recall of rare and long-term side effects. When used alone, constraints on the number of side effects generated reduce precision, and grounding outputs in clinician-curated side effect lists substantially improves reliability and robustness. These findings highlight important limitations of LLM use in oncology and suggest practical design choices for safer and more informative survivorship-focused applications.

What we could verify

These are the protocol signals we could actually recover from the available paper metadata. Use them to decide whether this paper is worth deeper reading.

Human Feedback Types

strong

Expert Verification

Directly usable for protocol triage.

"Accurately communicating the side effects of cancer treatments to cancer survivors is critical, particularly in settings such as informed consent, where clinicians must clearly and comprehensively convey potential treatment toxicities."

Evaluation Modes

strong

Automatic Metrics

Includes extracted eval setup.

"Accurately communicating the side effects of cancer treatments to cancer survivors is critical, particularly in settings such as informed consent, where clinicians must clearly and comprehensively convey potential treatment toxicities."

Quality Controls

missing

Not reported

No explicit QC controls found.

"Accurately communicating the side effects of cancer treatments to cancer survivors is critical, particularly in settings such as informed consent, where clinicians must clearly and comprehensively convey potential treatment toxicities."

Benchmarks / Datasets

missing

Not extracted

No benchmark anchors detected.

"Accurately communicating the side effects of cancer treatments to cancer survivors is critical, particularly in settings such as informed consent, where clinicians must clearly and comprehensively convey potential treatment toxicities."

Reported Metrics

strong

Precision, Recall

Useful for evaluation criteria comparison.

"Across models, we reveal sensitivity to minor documentation changes, trade-offs between precision and recall, and systematic under-recall of rare and long-term side effects."

Rater Population

strong

Domain Experts

Helpful for staffing comparability.

"Accurately communicating the side effects of cancer treatments to cancer survivors is critical, particularly in settings such as informed consent, where clinicians must clearly and comprehensively convey potential treatment toxicities."

Benchmarks and datasets

No benchmark or dataset names were extracted from the available abstract.

Reported metrics

precisionrecall
Human feedback details
Uses human feedback
Yes
Feedback types
Expert Verification
Rater population
Domain Experts
Expertise required
Medicine
Evaluation details
Evaluation modes
Automatic Metrics
Agentic eval
None
Quality controls
Not reported
Evidence quality
Moderate
Use this page as
Secondary protocol comparison source

Research brief

Metadata summary

Accurately communicating the side effects of cancer treatments to cancer survivors is critical, particularly in settings such as informed consent, where clinicians must clearly and comprehensively convey potential treatment toxicities.

Based on abstract + metadata only. Check the source paper before making high-confidence protocol decisions.

Key takeaways

  • Accurately communicating the side effects of cancer treatments to cancer survivors is critical, particularly in settings such as informed consent, where clinicians must clearly and comprehensively convey potential treatment toxicities.
  • However, this task remains challenging due to clinical knowledge deficits about adverse treatment effects and fragmentation across electronic health record (EHR) systems.
  • Large language models (LLMs) have the potential to assist in this task, though their reliability in oncology survivorship contexts remains poorly understood.

Researcher actions

  • Compare this paper against nearby papers in the same arXiv category before using it for protocol decisions.
  • Check the full text for explicit evaluation design choices (raters, protocol, and metrics).
  • Use related-paper links to find stronger protocol-specific references.

Caveats

  • Generated from abstract + metadata only; no PDF parsing.
  • Signals below are heuristic and may miss details reported outside the abstract.

Recommended queries

Contribution summary

  • We present a deployment-oriented stress-testing framework for evaluating LLM-generated radiation side effect lists in breast cancer treatment and survivorship care.

Researcher checklist

  • Human feedback protocol is explicit

    Detected: Expert Verification

  • Evaluation mode is explicit

    Detected: Automatic Metrics

  • Quality control reporting appears

    No calibration/adjudication/IAA control explicitly detected.

  • Benchmark or dataset anchors are present

    No benchmark/dataset anchor extracted from abstract.

  • Metric reporting is present

    Detected: precision, recall